Analysts Differ in Opinion on Jakafi Drug Maker Incyte (INCY)

Incyte Corp (NASDAQ:INCY) is one of the most undervalued stocks to buy and hold for 5 years. On January 27, Bank of America Securities analyst Tazeen Ahmad assigned a Buy rating to Incyte and set a $118 price target. This bullish ratings action stands in contrast to Wells Fargo’s downgrade of Incyte Corp (NASDAQ:INCY) to Equal Weight from Overweight on January 20. According to Wells Fargo, which also lowered the stock’s price target to $107 from $116, the downgrade reflects the company’s current valuation and limited near-term growth drivers.

Earlier this month, two analysts offered contrasting views on Incyte Corp (NASDAQ:INCY), particularly regarding its myelofibrosis medication Jakafi. On January 6, TD Cowen analyst Marc Frahm affirmed his Buy rating on the stock, citing the company’s transition beyond relying on Jakafi. However, on January 14, William Blair analyst Matt Phipps gave a hold rating on Incyte Corp (NASDAQ:INCY), noting that while the company seeks growth beyond Jakafi, it remains to be seen whether its next wave of products can offset the anticipated peak and decline of Jakafi revenues toward the end of the 2020s.

Incyte Corp (NASDAQ:INCY) is a biopharmaceutical company that discovers, develops, and commercializes proprietary therapeutics in hematology and oncology, as well as in inflammation and autoimmunity.

While we acknowledge the potential of INCY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 Most Undervalued Stocks to Buy and Hold for 5 Years and 14 Best Tech Stocks Under $10 to Buy

Disclosure: None. This article is originally published at Insider Monkey.